Business Context and Reporting Period
This Form 8-K is filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc., which was acquired by Miragen) on January 4, 2021, reporting events occurring on December 31, 2020. The filing details a special meeting of stockholders and subsequent corporate governance actions.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only quantitative data relates to capital structure and voting:
- Shares Outstanding (Pre-Conversion): 3,908,158 shares as of the record date (December 7, 2020).
- Shares Outstanding (Pro Forma): Approximately 30.8 million shares following the full conversion of Series A Non-Voting Convertible Preferred Stock.
- Authorized Shares: Increased from 100,000,000 to 200,000,000.
Material Changes
The following material changes were approved by stockholders and implemented:
- Capital Structure: Stockholders approved the issuance of Common Stock upon conversion of Series A Non-Voting Convertible Preferred Stock issued in October 2020.
- Authorized Capital: The Company amended its Certificate of Incorporation to double the number of authorized Common Stock shares.
- Equity Plan: The Miragen Therapeutics, Inc. Amended and Restated 2016 Equity Incentive Plan was approved.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of specific risks or contingencies beyond the standard regulatory disclosures regarding the voting process and Nasdaq compliance.
Investor Verification Checklist
- Verify the exact number of Series A Preferred shares converted and the resulting dilution impact on existing shareholders.
- Confirm the terms of the newly approved 2016 Equity Incentive Plan, including the pool size available for future grants.
- Review the impact of the 30.8 million pro forma share count on the company's market capitalization and per-share metrics.
- Check subsequent filings for the actual issuance date and registration statement details for the converted shares.